2023 / 01 / 12
Exhibition and Presentation at PEPTALK
Ajinomoto Bio-Pharma Services will participate in PEPTALK, on January 16 to 20, 2023.
This year’s event will feature world-renowned speakers, cutting-edge technologies, and engaging networking events. The program includes deep coverage of antibody discovery, protein engineering, bispecific antibodies, emerging immunotherapies, protein aggregation, machine learning, cell and gene therapy, protein expression, purification and production.
Ajinomoto Bio-Pharma Services will be making oral presentations, poster presentations and exhibiting its services and technologies at the conference.
We look forward to your visit.
| Event Name | PEPTALK |
|---|---|
| Dates | January 16(Mon) – 20(Fri), 2023 |
| Venue | HILTON SAN DIEGO BAYFRONT, CA |
| Exhibition | booth #512 |
Oral Presentation(1)
| Title and Presenters | Introduction of Biopharmaceutical Development and CORYNEX® Technology to Address Challenges in Manufacturing Hayato Nagano, Ajinomoto Co., Inc. |
|---|---|
| Abstract | Ajinomoto Bio-Pharma Services, as a fully integrated contract development and manufacturing organization (CDMO), offers a broad range of innovative platform technologies and end-to-end solutions for biopharmaceutical development and manufacturing. In this presentation, we will introduce our CDMO capability and CORYNEX® protein expression platform technology for biopharmaceuticals, which together can improve drug substance manufacturing. |
| Date, Time and Venue | January 18(Wed), 2023 12:45 PM at Aqua Salon AB |
Oral Presentation(2)
| Title and Presenters | Novel Format Conjugates and Multi-Specific Antibodies Produced by Chemical Site-Specific Conjugation: AJICAP® Yutaka Matsuda, Ajinomoto Co., Inc. |
|---|---|
| Abstract | Site-specific chemical conjugation technology (termed AJICAP®) is a simplified manufacturing process without using antibody engineering. We attempted to use site-specific conjugation technology to produce bispecific and trispecific antibodies with a new shape. The development of the unique methodology to produce homogeneous DAR = 1 conjugates enabled the production of homogeneous multispecific antibodies without a difficult purification process. Initial applications of AJICAP® technology to novel format conjugates are also discussed. |
| Date, Time and Venue | January 19th (Thr), 2023 9:50 AM at Aqua Salon D |
Poster Presentation(1)
| Title and Presenters | From peptides and small proteins to mAb, Ajinomoto’s proprietary microbial platform for pharmaceutical protein production Kazuo Yamagishi, Ajinomoto Co., Inc. |
|---|---|
| Abstract | We will introduce the cutting-edge technologies of Ajinomoto’s proprietary microbial secretory protein production. CORYNEX® : A bacterial recombinant protein expression system for antibody fragments and scaffolds. Endotoxin-free platform using Gram-positive bacteria as host cells. TALAMAX® : A system for the production of antibodies and antibody fragment fusion proteins using microbe. Compared to conventional antibody production using mammalian cells, culture time is half and the cost of raw materials is reduced to 1/10. |
| Poster track | C5B: Recombinant Protein Expression and Production |
Poster Presentation(2)
| Title and Presenters | ADC Therapeutic Window Enhancement Based on the Site-Specific Conjugation Platform: AJICAP® Conjugation Hiroki Imai, Ajinomoto Co., Inc. |
|---|---|
| Abstract | The chemical conjugation of antibodies in a site-directed manner remains an area of great interest and active efforts within the ADC community. In this poster, we present a novel platform named “AJICAP®” for the chemical and site-selective conjugation of native antibodies. Recent enhancements of the AJICAP® platform and conjugation at an additional Lys residue will be introduced. Therapeutic window enhancement will be also discussed. |
| Poster track | C2C: Safety and Efficacy of Bispecific Antibodies, ADCs and Combination Therapy |
Poster Presentation(3)
| Title and Presenters | Novel Format Conjugates and Multi-Specific Antibodies Produced by Chemical Site-Specific Conjugation: AJICAP® Yutaka Matsuda, Ajinomoto Co., Inc. |
|---|---|
| Abstract | A site-specific chemical conjugation is a well-known approach to producing homogeneous ADC with a simplified manufacturing process without an antibody engineering process. Aiming versatile manufacturing of multispecific antibodies, we attempted to apply site-specific conjugation technology to produce bispecific and trispecific antibodies as novel formats. Furthermore, the development of a unique methodology to produce homogeneous DAR = 1 conjugates enabled the production of homogeneous multispecific antibodies without a complicated purification process. |
| Poster track | C2C: Safety and Efficacy of Bispecific Antibodies, ADCs and Combination Therapy |